Kalaris Therapeutics (NASDAQ:KLRS) Rating Lowered to Sell at Wall Street Zen

Kalaris Therapeutics (NASDAQ:KLRS) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Sunday, Wall Street Zen reports.

Other research analysts have also recently issued reports about the company. Weiss Ratings cut Kalaris Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. TD Cowen assumed coverage on Kalaris Therapeutics in a research note on Monday, June 15th. They issued a “buy” rating for the company. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Kalaris Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $18.75.

Kalaris Therapeutics Stock Performance

Shares of KLRS opened at $3.30 on Friday. The firm has a market cap of $78.57 million, a price-to-earnings ratio of -1.63 and a beta of 0.22. Kalaris Therapeutics has a fifty-two week low of $3.03 and a fifty-two week high of $11.88. The firm has a 50 day moving average price of $4.01 and a 200-day moving average price of $5.30.

Kalaris Therapeutics (NASDAQ:KLRS) last released its earnings results on Tuesday, August 11th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.02. As a group, equities research analysts predict that Kalaris Therapeutics will post -1.99 earnings per share for the current year.

Institutional Investors Weigh In On Kalaris Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Kalaris Therapeutics in the fourth quarter valued at about $34,000. Sigma Planning Corp purchased a new stake in shares of Kalaris Therapeutics during the second quarter worth about $41,000. WealthTrust Asset Management LLC bought a new stake in shares of Kalaris Therapeutics in the first quarter worth about $72,000. Velan Capital Investment Management LP grew its stake in shares of Kalaris Therapeutics by 38.9% in the second quarter. Velan Capital Investment Management LP now owns 25,000 shares of the company’s stock worth $102,000 after purchasing an additional 7,000 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in Kalaris Therapeutics during the 2nd quarter valued at about $122,000. 66.05% of the stock is currently owned by institutional investors.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.